Why the study?
Does impaired CFVR LAD predict adverse cardiac outcomes in patients with asymmetric hypertrophic cardiomyopathy?
Does impaired CFVR LAD predict adverse cardiac outcomes in patients with asymmetric hypertrophic cardiomyopathy?
In patients with HCM, impaired CFVR LAD (≤2) strongly predicts adverse cardiac outcomes, making CFVR PD evaluation redundant for risk stratification.
No takes yet. Share an insight, caveat, or question.
Tešić et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: